Endocrine Abstracts

Objectives: Endogenous Cushing’s Syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol levels. Osilodrostat, a newly approved steroidogenesis inhibitor, has been shown to achieve fast and high rates of cortisol normalization, improving manifestations of hypercortisolism in patients with Cushing’s Disease (CD), a form of CS. We evaluated relative complete response (CR) ou...